The MarketWatch News Department was not involved in the creation of this content. MONTREAL, March 19, 2026 /PRNewswire/ -- Congruence Therapeutics today announced that the first participant has been ...
MONTREAL, Sept. 4, 2025 /PRNewswire/ -- Congruence, a computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein misfolding, ...
MONTREAL, March 19, 2026 /PRNewswire/ -- Congruence Therapeutics today announced that the first participant has been dosed in its Phase 1/1b clinical trial evaluating CGX-926, an oral small-molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results